Aarey Drugs & Pharmaceuticals Limited — Important, 04-12-2024: Updates

The Board of Directors of Aarey Drugs and Pharmaceuticals has approved the issuance of up to 50,00,000 convertible warrants, each convertible into one equity share at a face value of ₹10, on a preferential basis. The company plans to convene the 5th Extraordinary General Meeting on January 2, 2025, to seek shareholder approval for this issuance and related matters. CS Virendra Bhatt has been appointed as Scrutinizer for the e-voting process for this meeting. Additionally, the board approved the reappointment of Mr. Lalit Radha Krishna Tulsiani as an Independent Director for a second term from January 29, 2025, to January 28, 2030, and Mr. Anil Mandal for a second term from July 1, 2025, to June 30, 2030, both subject to shareholder approval. These developments indicate strategic moves aimed at strengthening governance and enhancing capital through new share offerings, potentially improving shareholder value. Investors should watch closely for further updates regarding the EGM and approval processes.